Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01602081 · ClinicalTrials.gov registry record
Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula
A clinical trial, sponsored by Cook Group Incorporated.
- Completed
- Registry status
- 28
- Enrollment target
NCT01602081: Completed study, sponsored by Cook Group Incorporated.
NCT01602081 is a clinical trial that has completed, run by Cook Group Incorporated. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01602081 has completed, sponsored by Cook Group Incorporated.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
The LIFT+Biodesign® study is a post-market observational study to evaluate the rate of fistula closure in patients with persistent trans-sphincteric anal fistula who receive the Biodesign® Tissue graft as part of their LIFT procedure.
Interventions
- DEVICE reinforce soft tissue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-01 |
What the finished NCT01602081 record still lists
NCT01602081 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which reinforce soft tissue is the first listed.
NCT01602081 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01602081 about?
NCT01602081 is a clinical study titled "Ligation of the Intersphincteric Fistula Tract (LIFT) + Biodesign for Anal Fistula". The LIFT+Biodesign® study is a post-market observational study to evaluate the rate of fistula closure in patients with persistent trans-sphincteric anal fistula who receive the Biodesign® Tissue graft as part of their LIFT procedure.
What is the current status of trial NCT01602081?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2013-01. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01602081?
The interventions under investigation include: reinforce soft tissue (DEVICE).
Who is sponsoring clinical trial NCT01602081?
This trial is sponsored by Cook Group Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia